Lung Cancer | Tumor

CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.

Meet the Visionary Defender of Early Detection and Prompt Treatment

November 6th 2021

Lung cancer is a dangerous and often silent killer for the residents of northeast Georgia. For Dr. Arfoosh, lung cancer screening, quick referrals and prompt treatment for people with newly diagnosed lung cancer are at the forefront of his daily work.

A Generous Caretaker for All Affected by Lung Cancer

November 5th 2021

After Kelsey Ahmed’s mother, Martha, was diagnosed with stage 4 non-small cell lung cancer, Kelsey and her family got to work raising funds and spreading awareness for the American Lung Association.

Side Effects From Immune Checkpoint Inhibitors May Increase Hospitalizations, Cost for Patients With Bladder, Liver, Lung or Skin Cancer

November 4th 2021

Patients who experience side effects due to immune checkpoint inhibitors are 80% more likely to go to the emergency room and have 30% higher monthly medical costs, compared to patients who did not have side effects.

Bringing the Lung Cancer Community Together Through Recognition

November 4th 2021

In this episode of CURE’s “Cancer Horizons” podcast, three individuals, who were recognized as CURE Lung Cancer Heroes, spoke about what the honor means to them and bringing the lung cancer community together.

Launching a Project to Change the Public Perception of Lung Cancer

November 4th 2021

By creating a community of survivors, researchers, physicians and clinicians, The White Ribbon Project — under Heidi Nafman-Onda’s direction — has influenced real change.

When Cancer Treatments Stop Working: Is it the End of the Line?

November 3rd 2021

When cancer treatments stop working, it is not the end of the line. Most patients with advanced disease will be on continuous therapy, and that means trying different options along the way.

FDA Approval of Tecentriq Marks ‘Major Advance’ for Pretreated NSCLC

November 2nd 2021

The FDA approval is based on ‘substantial’ disease-free survival results and may ‘drastically’ improve lung cancer survival.

Heroically Committed to Patients With Lung Cancer and Mesothelioma

October 31st 2021

"Dr. Rosenzweig’s commitment to helping patients with lung cancer and mesothelioma is truly heroic," several colleagues write.

Perseverance and Endurance in the Face of Lung Cancer

October 30th 2021

These are the powerful stories of real-life heroes in the lung cancer space who persevere with great compassion and teach us to embrace, not avoid, life’s setbacks and challenges.

American Success Story and Lung Cancer Hero

October 29th 2021

"Dr. Hossein came to the United States by himself in his teens as a political refugee from the turmoil in Iran," writes a colleague who nominated him for the Lung Cancer Heroes® Award. "Completely on his own and through his hard work, scholarship, initiative and refusal to let things get him down, he went to college and then to medical school."

CURE® Honors Oncologists, Patient Advocate in Lung Cancer Heroes® Award Program for Impact on Community

October 29th 2021

CURE®’s Lung Cancer Heroes® Award Program celebrates and thanks the heroes who make a difference in the lives of patients with lung cancer.

Hockey Hall of Famer Mike Bossy Diagnosed With Lung Cancer, Jill Biden Urges Women to Get Breast Cancer Screenings and More

October 22nd 2021

From former New York Islanders hockey player Mike Bossy announcing that he has lung cancer to First Lady Jill Biden emphasizing the importance of breast cancer screenings, here’s what’s happening in the cancer landscape this week.

First Patient With NTRK Fusion-Positive Tumor Treated in Phase 2 Trial of Taletrectinib

October 19th 2021

A company focused on treating underserved patients announced that the first patient with an NTRK fusion was dosed in a phase 2 trial of taletrectinib this summer.

FDA Approves Tecentriq for Pretreated NSCLC

October 15th 2021

The Food and Drug Administration approved adjuvant Tecentriq for patients with PD-L1—positive, stage 2 to 3A non-small cell lung cancer.

Trial Initiated for Chemoprotective Agent to Treat Non-Small Cell Lung Cancer

October 10th 2021

Aileron Therapeutics, Inc. announced the initiation of a clinical trial for ALRN-6924, a treatment for patients with non-small cell lung cancer.

Undergoing Genetic Testing for Non-Small Cell Lung Cancer

October 7th 2021

Allison Collins reflects on the genetic testing she underwent after receiving a non-small cell lung cancer diagnosis and describes the treatment options presented to her at that time.

Losing a Spouse During Cancer Treatment: ‘If You Are Alive, Then You Need to Live’

September 30th 2021

A woman explains how she received a lung cancer diagnosis while she was caring for her sick husband and what it was like to lose him in this episode of the “CURE® Talks Cancer” podcast.

NSCLC: Understanding Staging and Diagnostic Testing

September 30th 2021

Dr. Vamsidhar Velcheti provides an expert’s insight on the testing and staging that must be performed during a diagnosis of non-small cell lung cancer.

Navigating Emotional Response to a Lung Cancer Diagnosis

September 30th 2021

Considerations for the emotional impact of a lung cancer diagnosis and how patients can be supported during their treatment journey.

Receiving a Diagnosis of Non-Small Cell Lung Cancer

September 30th 2021

Allison Collins describes her diagnosis with KRAS-positive non-small cell lung cancer and the symptoms that led her to seek medical attention.

Exkivity FDA Approval a ‘Compelling’ Solution as First Oral Therapy for Lung Cancer Subset

September 28th 2021

Here’s what patients should know about the recent FDA approval of Exkivity, the first oral therapy for patients with non-small cell lung cancer who have EFGR exon 20 insertion mutations.

Some Areas Lag Behind in Decreasing Lung Cancer Death Rates

September 27th 2021

Geographic disparities at the state-level are leading to increased rates of death from lung cancer, according to an expert.

First Patient With Lung Cancer Treated in Phase 2b Tomivosertib Trial

September 24th 2021

The first patient was treated in the phase 2b KICKSTART trial testing the safety and efficacy of tomivosertib in combination with Keytruda.

Age, Other Health Factors Can Play a Role in Cancer Treatment Decisions

September 23rd 2021

The prescription of systemic cancer therapies varies based on a patient’s age, comorbidities, cancer stage and other variables, according to recent research.

Resources and Tools for Non-Small Cell Lung Cancer

September 23rd 2021

Ms. Addario, lung cancer survivor, encourages patients with non-small cell lung cancer to use all the resources and tools that are available to them.

Advocacy and Education for Biomarker Testing in Non-Small Cell Lung Cancer

September 23rd 2021

Ms. Addario shares the promising hope for patients with lung cancer and describes the steps in the process of biomarker testing for patients with lung cancer.

Treatment Targets in Non-Small Cell Lung Cancer

September 23rd 2021

Treating patients with lung cancer by identifying specific biomarkers to use the correct combination therapy and what it means for a biomarker to be actionable.

Medicare Eligibility May Be Associated With More Cancer Diagnoses

September 16th 2021

The eligible age of 65 years for Medicare may be discouraging patients from getting screenings and tests as they wait for more health coverage.

FDA Approves Exkivity as First Oral Therapy for Lung Cancer Subset

September 15th 2021

The FDA’s approval of Exkivity marks the first approved oral therapy for this subgroup of patients with non-small cell lung cancer.

Immunotherapy Offers Certain Patients With Small Cell Lung Cancer A ‘Ray of Hope’, Expert Says

September 15th 2021

Although immunotherapy has provided patients with small cell lung cancer with a “light at the end of the tunnel,” an expert from City of Hope argues more research is needed.